Revance Therapeutics Releases First Quarter 2015 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Revance Therapeutics Releases First Quarter 2015 Financial Results

NEWARK, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq: RVNC ), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, announced today financial results for the first quarter ended March 31, 2015.

Recent Highlights

  • Completed enrollment for BELMONT Phase 2 active comparator trial. The study is evaluating the safety, efficacy and duration of effect of the company's injectable RT002 product candidate to treat glabellar (frown) lines.
  • Completed enrollment in the open-label study for the company's topical RT001 product candidate for the treatment of lateral canthal (crow's feet) lines.
  • Prioritized cervical dystonia as the first therapeutic indication for the company's RT002 Phase 2 clinical trial in a muscle movement disorder.

"We have made significant progress in 2015 with our neurotoxin product candidates in four unique indications," said President and Chief Executive Officer, Dan Browne. "Our injectable RT002 BELMONT study, a Phase 2 active comparator clinical trial against the market leader for the treatment of frown lines, has completed enrollment. Our prior study showed a median duration of effect of seven months and we look forward to reporting interim duration results from the BELMONT study later this year.

"In addition, we are pleased to announce that we have selected cervical dystonia as our first therapeutic indication for injectable RT002. Cervical dystonia is characterized by excessive pulling of the muscles in the neck and shoulder and, as a result, negatively impacts functionality and quality of life. Since cervical dystonia is already an approved indication for botulinum toxin, we have a clear clinical and regulatory path to follow for approval. We believe physicians and patients alike would embrace a potentially longer-lasting botulinum toxin treatment option for this disorder. We plan to commence a Phase 2 clinical trial in the second half of 2015 and report preliminary efficacy results before year end.

"Our product candidate RT001 has the potential to be the first commercially-available, topically-applied form of botulinum toxin type A and maintains an exceptional safety profile. Our open-label study is now fully enrolled, and we anticipate reporting the outcome this quarter. Following a successful readout from the open-label study, we plan to initiate a Phase 3 Pivotal trial for crow's feet lines this summer and report preliminary efficacy results before the end of the year. Separately, we plan to initiate an RT001 Phase 2 clinical study mid-year for the treatment of hyperhidrosis, or excessive sweating, and report preliminary efficacy results in the second half of 2015," Browne concluded.

Summary Financial Results

Research and development expenses for the quarter ended March 31, 2015 were $9.3 million compared to $7.6 million for the same period in 2014. The increase in research and development expenses is primarily attributable to increased costs related to personnel and expenditures related to our ongoing clinical trials.

General and administrative expenses for the quarter ended March 31, 2015 were $6.0 million compared to $4.1 million for the same period in 2014. The increase in general and administrative expenses is primarily attributable to increased costs related to personnel and administrative activities to support the operation of a public company.

Total operating expenses for the quarter ended March 31, 2015 were $15.3 million compared to $11.6 million for the same period in 2014. Stock-based compensation for the quarter ended March 31, 2015 was $2.3 million. When excluding depreciation and stock-based compensation, total operating expenses for the quarter ended March 31, 2015 were $12.4 million.

Net loss for the quarter ended March 31, 2015 was $15.4 million compared to $21.4 million for the same period in 2014. Interest expense for the quarter ended March 31, 2015 was $0.2 million. Upon completion of the IPO in February 2014, Revance recorded non-cash interest expense, including loss on debt extinguishment, of $9.6 million in connection with the settlement of previously outstanding convertible notes.

Cash and cash equivalents as of March 31, 2015 were $153.7 million.

2015 Financial Outlook

Revance reaffirms its 2015 full-year guidance. The company expects cash burn for 2015 to be in the range of $74 to $84 million. Revance expects 2015 non-GAAP operating expense to be in the range of $72 to $80 million, excluding depreciation of $2 to $3 million and estimated stock-based compensation of $10 to $12 million. With additional clinical trials planned for 2015, the company anticipates 2015 non-GAAP research and development expense to be in the range of $52 to $60 million, excluding depreciation of $2 to $3 million and estimated stock-based compensation of $5 to $7 million.

Weighted-average number of shares outstanding for the first quarter ended March 31, 2015 was 23.5 million. Revance expects 2015 weighted-average number of shares outstanding to be approximately 23.5 million to 24.5 million.

Conference Call

Individuals interested in listening to the conference call today, May 13, at 1:30pm PT/4:30pm ET may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference ID: 22992568; or from the webcast link in the investor relations section of the Company's website at: www.revance.com .

A replay of the call will be available beginning May 13, 2015 at 4:30pm PT/7:30pm ET through midnight on May 14, 2015. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 22992568. The webcast will be available in the investor relations section on the Company's website for 30 days following the completion of the call.

RT001 and RT002 Product Candidates

Revance is currently developing two botulinum toxin type A product candidates. RT001 is a topical formulation, which has the potential to be the first commercially available non-injectable dose form. Revance is studying topical RT001 for aesthetic indications, such as crow's feet lines (wrinkles around the eyes) and therapeutic indications such as hyperhidrosis (excessive sweating). RT002 is a novel, injectable formulation of botulinum toxin designed to be more targeted and longer lasting than currently available injectable botulinum toxin products. Revance is studying injectable RT002 for aesthetic indications, such as glabellar (frown) lines and therapeutic uses, such as muscle movement disorders. Both products would have the potential to expand into additional aesthetic and therapeutic indications in the future.

About Revance Therapeutics, Inc.

Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin A through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. Revance is pursuing clinical development for product candidates topical RT001 and injectable RT002 in a broad spectrum of aesthetic and therapeutic indications. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform. More information on Revance Therapeutics can be found at www.revance.com .

"Revance Therapeutics", TransMTS® and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to Revance Therapeutics' 2015 Financial Outlook and other financial performance, the process and timing of, and ability to complete, current and anticipated future clinical development of our product candidates, including but limited to initiation and design of clinical studies for current and future indications, related results and reporting of such results; statements about our business strategy, goals and market for our anticipated products, plans and prospects; our ability to obtain regulatory approval; potential benefits of our product candidates and our technologies; and future financial performance.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome, cost and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our product candidates; our ability to obtain funding for our operations; our plans to research, develop and commercialize our product candidates; our ability to achieve market acceptance of our product candidates; unanticipated costs or delays in research, development and commercialization efforts; the applicability of clinical study results to actual outcomes; the size and growth potential of the markets for our product candidates; our ability to successfully commercialize our product candidates and the timing of commercialization activities; the rate and degree of market acceptance of our product candidates; our ability to develop sales and marketing capabilities; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; our ability to continue obtaining and maintaining intellectual property protection for our product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Revance's periodic filings with the Securities and Exchange Commission (the "SEC"), including factors described in the section entitled described in the "Risk Factors" section of our annual report on Form 10-K filed March 4, 2015. These forward-looking statements speak only as of the date hereof. Revance disclaims any obligation to update these forward-looking statements.

Use of Non-GAAP Financial Measures

Revance has presented certain non-GAAP financial measures in this release. This release and the reconciliation tables included herein include total non-GAAP operating expense and non-GAAP R&D expense, both of which exclude depreciation and stock-based compensation. Revance excludes depreciation costs and stock-based compensation expense because management believes the exclusion of these items is helpful to investors to evaluate Revance's recurring operational performance. Revance management uses these non-GAAP financial measures to monitor and evaluate its operating results and trends on an on-going basis, and internally for operating, budgeting and financial planning purposes. The non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for or superior to GAAP results.

 
 
REVANCE THERAPEUTICS, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
(Unaudited)  
 
  March 31, December 31,
  2015 2014
ASSETS    
CURRENT ASSETS    
Cash and cash equivalents $ 153,717 $ 171,032
Restricted cash, current portion 35 75
Prepaid expenses and other current assets 1,937 1,624
Total current assets 155,689 172,731
Property and equipment, net 19,390 19,274
Restricted cash, net of current portion 400 435
Other non-current assets 243 29
TOTAL ASSETS $ 175,722 $ 192,469
LIABILITIES AND STOCKHOLDERS' EQUITY    
CURRENT LIABILITIES    
Accounts payable $ 2,089 $ 3,149
Accruals and other current liabilities 4,019 4,145
Financing obligation, current portion 319 307
Notes payable, current portion and net of discount — 2,635
Total current liabilities 6,427 10,236
Financing obligation, net of current portion 513 598
Derivative liabilities associated with Medicis settlement 1,583 1,541
Deferred rent 3,741 3,725
TOTAL LIABILITIES 12,264 16,100
Commitments and Contingencies    
STOCKHOLDERS' EQUITY    
Common stock, par value $0.001 per share — 95,000,000 shares authorized both as of March 31, 2015 and December 31, 2014, respectively; 23,944,861 and 23,774,465 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively 24 24
Additional paid-in capital 437,633 435,142
Accumulated deficit (274,199) (258,797)
TOTAL STOCKHOLDERS' EQUITY 163,458 176,369
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 175,722 $ 192,469
 
 
REVANCE THERAPEUTICS, INC.
 
Condensed Consolidated Statement of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(Unaudited)
 
  Quarter Ended March 31,
  2015 2014
Revenue $ 75 $ 158
Operating expenses:    
Research and development 9,254 7,551
General and administrative 5,996 4,093
Total operating expenses 15,250 11,644
Loss from operations (15,175) (11,486)
Interest income 27 2
Interest expense (165) (9,841)
Change in fair value of derivative liabilities associated with the convertible notes — 4,032
     
Changes in fair value of derivative liabilities associated with Medicis settlement (42) (416)
     
Change in fair value of common stock warrant liability — (2,151)
Change in fair value of convertible preferred stock warrant liability — (210)
     
Loss on settlement of preferred stock warrant — (1,356)
Other expense, net (47) —
Net and comprehensive loss $ (15,402) $ (21,426)
Net loss attributable to common stockholders:    
Basic $ (15,402) $ (21,426)
Diluted $ (15,402) $ (21,426)
Net loss per share attributable to common stockholders:    
Basic $ (0.65) $ (1.93)
Diluted $ (0.65) $ (1.93)
Weighted-average number of shares used in computing net loss per share attributable to common stockholders:    
Basic 23,535,080 11,092,471
Diluted 23,535,080 11,092,471
 
 
Revance Therapeutics, Inc.
2015 Financial Results
 
Reconciliation of GAAP Operating Expense to Non-GAAP Expense
(In thousands)
 
  Quarter Ended March 31, 2015
Operating expense:  
GAAP operating expense $ 15,250
Adjustments:  
Stock-based compensation (2,317)
Depreciation (531)
Non-GAAP operating expense $ 12,402

 

Revance Therapeutics, Inc.
Financial Guidance
 
Reconciliation of GAAP Operating Expense to Non-GAAP Expense
(In thousands)
 
  Fiscal Year
  2015
  Low High
Operating expense:    
GAAP operating expense $ 84,000 $ 95,000
Adjustments:    
Stock-based compensation (10,000) (12,000)
Depreciation (2,000) (3,000)
Non-GAAP operating expense $ 72,000 $ 80,000
 
 
Reconciliation of GAAP R&D Expense to Non-GAAP R&D Expense
(In thousands)
 
  Fiscal Year
  2015
  Low High
Operating expense:    
GAAP R&D expense $ 59,000 $ 70,000
Adjustments:    
Stock-based compensation (5,000) (7,000)
Depreciation (2,000) (3,000)
Non-GAAP R&D expense $ 52,000 $ 60,000

Investors: Revance Therapeutics Jeanie Herbert (714) 325-3584 Westwicke Partners Leigh Salvo (415) 513-1281 Trade Media: Nadine Tosk (847) 920-9858

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 0

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 177

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Gayatri Pariwar Celebrates 100 Years with Massive Yoga Event

Updated Category News Views 52

An Impressive Centenary for Gayatri Pariwar Sometimes, you get hit by a wave so big you can't ignore it, and Gayatri Pariwar's centennial festival in New Delhi was one such tsunami. Picture this: countless souls gathered to mark a hundred years of spiritual and social reform, not just with chants and talks, but through an awe-inspiring mass yoga event. In my decades...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 231

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 459

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 23

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 54

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 46

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 373

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 142

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading

Top 5 Most Recently Viewed Articles

Bitcoin’s Price Dynamics: Labor Reports and Elections Impacting Trends

Updated Category News Views 197

Labor Market Reports and Bitcoin's Future Into The Cryptoverse founder Benjamin Cowen shares insights on the current trajectory of Bitcoin as market dynamics shift with upcoming labor market reports and election results. Market Predictions Impacted by External Factors Cowen emphasizes that predictions in the short term remain complex. He notes that the momentum of the...

Continue Reading
Wearable Materials Market Forecast: Growth to USD 9.14 Billion

Updated Category News Views 238

Overview of the Wearable Materials Market The Wearable Materials Market is on an impressive trajectory, with an anticipated growth from USD 3.24 billion in 2024 to USD 9.14 billion by 2032. This surge represents a compounded annual growth rate (CAGR) of 13.85% during the forecast years. Such expansion is astonished by the increasing demand for wearables associated with...

Continue Reading
Strengthening Ties: Xi Jinping and Singaporean PM Wong Unite

Updated Category News Views 382

Strengthening Bilateral Relations for a Brighter Future In a significant meeting that highlights the growing ties between China and Singapore, President Xi Jinping recently welcomed Singaporean Prime Minister Lawrence Wong in Beijing. This engagement underscores the deepening friendship and collaboration between the two nations. During their discussions, President Xi...

Continue Reading
Exploring the Rapid Growth of the Virtual Cards Market

Updated Category News Views 154

Overview of the Virtual Cards Market The global virtual cards market is poised for substantial growth, with estimates suggesting an increase of USD 428.6 billion from 2025 to 2029. A significant annual growth rate of 17.1% during this period is projected, reflecting the ongoing transformations in the payment landscape, particularly driven by advancements in technology and...

Continue Reading
Appian Introduces Advanced AI Features to Revolutionize Workflow

Updated Category News Views 240

Transforming Business Processes with AI Appian, renowned for its innovative process automation solutions, has just rolled out significant enhancements to its platform. By embedding sophisticated AI agents into enterprise workflows, Appian is making strides in automating complex tasks, and empowering business users to revamp outdated applications seamlessly. Empowering...

Continue Reading